Seven Fleet Capital Management LP Has $4.79 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX

Seven Fleet Capital Management LP lifted its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 218.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 43,052 shares of the company’s stock after purchasing an additional 29,553 shares during the quarter. Abivax accounts for approximately 1.5% of Seven Fleet Capital Management LP’s holdings, making the stock its 19th biggest holding. Seven Fleet Capital Management LP’s holdings in Abivax were worth $4,794,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ABVX. TCG Crossover Management LLC lifted its holdings in Abivax by 17.4% during the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after purchasing an additional 1,055,000 shares during the last quarter. UBS Group AG grew its stake in Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after buying an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. grew its stake in Abivax by 0.4% during the fourth quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock worth $439,714,000 after buying an additional 14,000 shares during the last quarter. Morgan Stanley increased its holdings in shares of Abivax by 114.3% during the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after buying an additional 1,681,277 shares in the last quarter. Finally, Vestal Point Capital LP increased its holdings in shares of Abivax by 90.0% during the fourth quarter. Vestal Point Capital LP now owns 1,900,000 shares of the company’s stock worth $256,224,000 after buying an additional 900,000 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Trading Up 0.5%

Shares of NASDAQ:ABVX opened at $124.92 on Friday. Abivax SA Sponsored ADR has a 1-year low of $67.09 and a 1-year high of $148.83. The stock has a market capitalization of $10.90 billion, a P/E ratio of -23.98 and a beta of 0.87. The business has a 50-day moving average price of $118.54 and a two-hundred day moving average price of $118.41.

Abivax (NASDAQ:ABVX) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, equities analysts predict that Abivax SA Sponsored ADR will post -3.22 EPS for the current year.

Wall Street Analyst Weigh In

ABVX has been the topic of several recent analyst reports. Leerink Partners boosted their target price on Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. Jefferies Financial Group raised Abivax from a “hold” rating to a “buy” rating and raised their price target for the company from $108.00 to $158.00 in a report on Tuesday, June 30th. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Wedbush boosted their price objective on Abivax from $90.00 to $110.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 30th. Finally, Citigroup restated an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $156.50.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.